Literature DB >> 10555934

Rotavirus disease and its prevention in infants and children.

M A Raebel1, B S Ou.   

Abstract

Rotavirus disease causes immense morbidity and mortality in developing countries. In the United States, mortality is very rare, but the health care and societal costs of rotavirus-related morbidity exceed one billion dollars annually A new vaccine that prevents the illness recently was marketed in the United States. Economic issues surround national recommendations for its use. Economic, safety, and effectiveness issues will be resolved only with surveillance systems that document the effectiveness of immunization programs and their cost-effectiveness.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10555934     DOI: 10.1592/phco.19.16.1279.30875

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

Review 1.  Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial.

Authors:  M Van der Wielen; P Van Damme
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-20       Impact factor: 3.267

2.  Measuring the Impact of Rotavirus Acute Gastroenteritis Episodes (MIRAGE): A prospective community-based study.

Authors:  Martin Sénécal; Marc Brisson; Marc H Lebel; John Yaremko; Richard Wong; Lee Ann Gallant; Hartley A Garfield; Darryl J Ableman; Richard L Ward; John S Sampalis; James A Mansi
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

3.  Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?

Authors:  Stefanie Knoll; Christoph Mair; Ursula Benter; Katja Vouk; Baudouin Standaert
Journal:  Health Econ Rev       Date:  2013-11-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.